Mylan to pay $465 mn to settle allegations it overcharged Medicaid for EpiPen

The settlement with the Department of Justice and other regulators resolves questions abou
AFP

New York (AFP) – Mylan will pay $465 million to resolve accusations from regulators that it overbilled the federal Medicaid program for the EpiPen allergy medication, the drugmaker announced Friday.

The settlement with the Department of Justice and other regulators resolves questions about Mylan’s classification of EpiPen as a generic drug, Mylan said. 

Regulators have said the misclassification contributed to a swelling of payments to Mylan, which nearly monopolizes the market for the allergy injectors, for EpiPen under federal health care programs. 

COMMENTS

Please let us know if you're having issues with commenting.